Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
sNN0029 Continuation Study in ALS
NCT01384162Phase 2Terminated
- Sponsor
- Newron Pharmaceuticals
- Start
- Jun 2009
- Primary completion
- Oct 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of telbermin in amyotrophic lateral sclerosis (ALS), sponsored by Newron Pharmaceuticals. Started Jun 2009; status: terminated.
02
Drugs
telbermin
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT01384162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01384162.